Coxicare

Etoricoxib

Symptomatic relief of RA, OA & acute gouty arthritis.

OA 30 mg once daily, increased to 60 mg once daily if necessary. RA 90 mg once daily. Acute gouty arthritis 120 mg once daily, max of 8 days. Mild hepatic impairment (Child-Pugh score 5-6) Max: 60 mg once daily. Moderate hepatic impairment (Child-Pugh score 7-9) Max: 60 mg every other day or 30 mg once daily.

May be taken with or without food.

Hypersensitivity. History of asthma, urticaria, or other allergic reactions after taking aspirin or other NSAIDs. CHF (NYHA II-IV). Patients w/ HTN whose BP is persistently elevated >140/90 mmHg & has not been adequately controlled. Established ischaemic heart disease, peripheral arterial disease &/or cerebrovascular disease (including patients who have recently undergone CABG surgery or angioplasty). Severe hepatic dysfunction (serum albumin <25 g/L or Child-Pugh score ≥10), active peptic ulceration or GI bleeding. Estimated CrCl <30 mL/min. Should not be used as adjunctive therapy w/ other NSAIDs.

Risk of thrombotic events (especially MI & stroke). Patients w/ significant risk factors for CV events (including those w/ diabetes, HTN, hypercholesterolaemia, 1st degree relative w/ ischaemic heart disease, cardiac failure or who are smokers). Not a substitute for aspirin in CV prophylaxis. May develop upper GI ulcers/ulcer complications. Further increase in risk of GI adverse effects (GI ulceration or other GI complications) when taken concomitantly w/ ASA (even at low doses). Renal papillary necrosis & other renal injury in long-term use. Monitoring of renal function in patients w/ pre-existing significantly impaired renal function, uncompensated heart failure, or cirrhosis. Patients w/ considerable dehydration. Patients w/ history of cardiac failure, left ventricular dysfunction, or HTN & w/ pre-existing oedema from any other reason. Elevation of AST &/or ALT. Exfoliative dermatitis, SJS & TEN. Discontinue at the 1st appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. Exacerbation of inflammatory bowel disease associated w/ spondyloarthropathies. May mask fever & infection. May affect ability to drive & operate machinery. Do not use during 1st & 2nd trimesters of pregnancy & avoid during 3rd trimester of pregnancy. Lactation. Childn <18 yr. Elderly.

Excessive fluid retention in the body tissues, resulting in oedema; dizziness; headache; HTN; palpitations; disturbances of the gut eg, diarrhoea, nausea, indigestion, flatulence or abdominal pain; feeling weak or fatigued; cold or flu-like symptoms.

May diminish antihypertensive effect of diuretics, ACE inhibitors & AIIA. Increases the rate of GI ulceration or other complications w/ low-dose aspirin. May reduce natriuretic effect of frusemide & thiazides. Increased AUC w/ ketoconazole. Elevation of plasma levels/conc & reduction in renal clearance of lithium & MTX. Increased steady state & exposure of OCs (ethinyl estradiol). Increased oestrogenic conc of HRT. Decreased plasma AUC w/ rifampicin. Increased risk of bleeding w/ warfarin.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AH05 - etoricoxib ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, coxibs.

Rx